Aslera Safety "Still Open," FDA Cmte. Says; Surveillance Study Needed
Executive Summary
Genelabs/Watson Aslera should have a surveillance monitoring requirement to generate additional safety information, FDA Arthritis Advisory Committee Acting Chair Nigel Harris, MD, Morehouse School of Medicine, indicated during review of the drug.
You may also be interested in...
Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted
Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.
Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted
Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.
Genelabs Aslera May Offer Some Efficacy For Treatment Of Lupus - FDA Cmte.
Genelabs Aslera may offer some clinical utility for the treatment of patients with mild to moderate systemic lupus erythematosus, FDA Arthritis Advisory Committee members indicated April 19.